|1 Table of Contents 3
|1.1 List of Tables 5
|1.2 List of Figures 5
2 Introduction 7
2.1 What Is This Report About? 7
2.2 Drug Delivery Devices Market Segmentation 7
2.3 Definitions of Markets Covered in the Report 8
3 Drug Delivery Devices Market, China 10
3.1 Drug Delivery Devices Market, China, Revenue ($m), 2018-2033 10
3.2 Drug Delivery Devices Market, China, Revenue Mix ($m), 2023 11
3.3 Drug Delivery Devices Market, China, Category Contribution by Revenue ($m), 2023 12
3.4 Drug Delivery Devices Market, China, Revenue ($m), 2018-2033 13
3.5 Drug Delivery Devices Market, China, Volume (Units), 2018-2033 15
3.6 Drug Delivery Devices Market, China, Volume (Units), 2018-2033 16
3.7 Drug Delivery Devices Market, China, Company Share by Revenue ($m), 2023 18
4 Central Venous Catheters Market, China 20
4.1 Central Venous Catheters Market, China, Revenue Mix ($m), 2023 20
4.2 Central Venous Catheters Market, China, Segment Contribution (%), 2023 21
4.3 Central Venous Catheters Market, China, Revenue ($m), 2018-2033 22
4.4 Central Venous Catheters Market, China, Volume (Units), 2018-2033 24
4.6 Central Venous Catheters Market, China, Average Price ($) , 2018-2033 26
4.7 Central Venous Catheters Market, China, Distribution Share by Revenue ($m), 2023 27
4.8 Central Venous Catheters Market, China, Company Share by Revenue ($m), 2023 28
5 Implantable Ports Market, China 30
5.1 Implantable Ports Market, China, Revenue Mix ($m), 2023 30
5.2 Implantable Ports Market, China, Segment Contribution (%), 2023 31
5.3 Implantable Ports Market, China, Revenue ($m), 2018-2033 32
5.4 Implantable Ports Market, China, Volume (Units), 2018-2033 34
5.5 Implantable Ports Market, China, Average Price ($) , 2018-2033 36
5.6 Implantable Ports Market, China, Distribution Share by Revenue ($m), 2023 37
5.7 Implantable Ports Market, China, Company Share by Revenue ($m), 2023 38
6 Infusion Systems Market, China 39
6.1 Infusion Systems Market, China, Revenue Mix ($m), 2023 39
6.2 Infusion Systems Market, China, Segment Contribution (%), 2023 40
6.3 Infusion Systems Market, China, Revenue ($m), 2018-2033 41
6.3.1 Infusion Pump Disposables Market, China, Revenue ($m), by Segment, 2018-2033 43
6.3.2 Infusion Pumps Market, China, Revenue ($m), by Segment, 2018-2033 45
6.4 Infusion Systems Market, China, Volume (Units), 2018-2033 47
6.4.1 Infusion Pump Disposables Market, China, Volume (Units), by Segment, 2018-2033 49
6.4.2 Infusion Pumps Market, China, Volume (Units), by Segment, 2018-2033 51
6.5 Infusion Systems Market, China, Average Price ($) , 2018-2033 53
6.6 Infusion Systems Market, China, Distribution Share by Revenue ($m), 2023 54
6.7 Infusion Systems Market, China, Company Share by Revenue ($m), 2023 55
7 Overview of Key Companies in China, Drug Delivery Devices Market 56
7.1 Becton Dickinson and Co 56
7.1.1 Company Overview 56
7.2 B. Braun Melsungen AG 56
7.2.1 Company Overview 56
7.3 Baxter International Inc 56
7.3.1 Company Overview 56
7.4 Teleflex Inc 56
7.4.1 Company Overview 56
8 Drug Delivery Devices Market Pipeline Products 57
9 Financial Deals Landscape 65
9.1 Acquisition 65
9.1.1 Otsuka Holdings May Sell Stake in MicroPort Scientific 65
9.1.2 Sunshine Lake Pharma to Acquire Yichang Hec Changjiang Pharma 66
9.2 Equity Offerings 67
9.2.1 Lvkang Biochemical to Raise USD11 Million in Public Offering of Shares 67
9.3 Venture Financing 68
9.3.1 Changzhou Taimeirui Biotechnology Secures USD1.415 Million in Angel Funding 68
9.3.2 Zhejiang Haigetang Pharma Secures Series A Financing 69
9.3.3 Shanghai Injexin Medical Technology Raises Funds through Series A Financing 70
9.3.4 Guangzhou Aidi Gene Technology (Eddie Gene, Aidigene) Raises Approximately USD1.39 Million in Angel Financing 71
9.3.5 Suzhou Hanerxi Medical Device Development (Hanxi Medical) Raises Funds through Series B Financing 72
10 Recent Developments 74
10.1 Corporate Communications 74
10.1.1 May 07, 2024: Yichang Hec Changjiang Pharmaceutical Notice of Annual General Meeting 74
10.2 Financial Announcements 74
10.2.1 Aug 14, 2024: Solasia Pharma Reports Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2024 74
10.2.2 Aug 14, 2024: Glenmark Pharma Reports Consolidated Revenue Growth of
6.9%, EBITDA Margin of
18.1% and PAT Margin of
10.5% YoY for Q1 FY 2024-25 74
10.2.3 Aug 12, 2024: Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update 75
10.2.4 Aug 06, 2024: Cellectis Provides Financial Results for the Second Quarter 2024 76
10.3 Government and Public Interest 78
10.3.1 Jun 13, 2024: Direct Delivery of Oligonucleotide Drugs to the CNS and Common Histopathological Changes 78
10.4 Legal And Regulatory 79
10.4.1 Apr 15, 2025: Hangzhou SHINING3D Dental Technology Receives 510(K) Clearance For DT20 Denture Base Resin 79
10.4.2 May 29, 2024: Gan & Lee Pharmaceuticals Pass the EMA Pre-Approval (GMP) Inspection 79
10.5 Other Significant Developments 79
10.5.1 Apr 23, 2025: Nanologica Receives Order Worth USD 180,000 from New Customer in China 79
10.5.2 Dec 03, 2024: Nanologica Receives Order on Nlab Saga Valued at Approx Sek 1,9 Million 80
10.6 Product News 80
10.6.1 Aug 01, 2024: Nonclinical Safety Evaluation Of Ocular Drug Delivery Using Cynomolgus Macaques 80
10.6.2 Aug 01, 2024: Advancing CNS And CGT Research: Prisys Biotechnologies Leading The Way 81
10.6.3 Jun 13, 2024: Direct Delivery Of the Oligonucleotide Drugs To The CNS And Common Histopathological Changes 82
11 Appendix 83
11.1 Research Methodology 84
11.1.1 Coverage 84
11.1.2 Secondary Research 84
11.1.3 Primary Research 85
11.1.4 Market Modeling and Forecasting 86
11.1.5 Company Share Analysis 87
11.1.6 Distribution Share Analysis 87
11.1.7 Benchmarking 88
11.2 GlobalData Consulting 88
11.3 Contact Us 88
11.4 Disclaimer 89